# Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

> **NCT01786538** · PHASE3 · WITHDRAWN · sponsor: **Asan Medical Center**

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib/FOLFOX
- **DRUG:** Placebo/FOLFOX

## Key facts

- **NCT ID:** NCT01786538
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-06
- **Primary completion:** 2016-05
- **Final completion:** 2017-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786538, "Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT01786538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*